Drug-related nail disease.
Drug-induced nail abnormalities can present with a wide variety of clinical manifestations that are often dose-related and that disappear after drug withdrawal. Some nail changes are asymptomatic and only cause cosmetic problems, whereas others cause pain and discomfort and impair manual activities or deambulation. New side effects have been recently observed with different groups of anticancer agents. These include painful onycholysis and subungual abscesses caused by taxanes and anthracyclines (eg, doxorubicin) in addition to ingrown nails, paronychia, and pyogenic granuloma associated with the use of tyrosine kinase inhibitors of the epidermal growth factor receptor (eg, erlotinib, gefitinib).
Department of Specialised Experimental and Diagnostic Medicine University of Bologna, Italy. Electronic address: biancamaria.piraccini@unibo.it.
Bianca Maria
BM
Piraccini
Aurora
A
Alessandrini
D000970:Antineoplastic Agents / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D005385:Fingers; D017789:Granuloma, Pyogenic / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced; D017496:Hypopigmentation / Q000139:chemically induced; D009260:Nail Diseases / Q000139:chemically induced*; D054039:Onycholysis / Q000139:chemically induced; D010304:Paronychia / Q000139:chemically induced; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D014034:Toes
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors